Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.
Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.